1.4.10.13 - TETRAOXA -7.16-DIAZACYCLOACTADECANE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

The invention relates to partially novel metal complexes, salts and double salts of 1,4,10,13-tetraoxa-7,16-diazacyclooctadecane compounds of formula (I), wherein Q and Q mean hydrogen or a group of formula (III), in the groups of formula (III) the R substituents independently represent hydrogen, a C1-5 straight or branched chain alkyl group, a C2-5 straight or branched chain alkenyl group, phenyl or phenyl-C1-5alkyl group, the two latter ones optionally being substituted on their aromatic part by one or more halogen(s), C1-5alkyl, C1-5alkoxy, cyano or nitro group(s), with the proviso that at least one of Q and Q is other than hydrogen; Me stands for an alkaline metal or alkaline earth metal or transition metal ion; q is 0 or 1; M and N, independently from each other, stand for hydrogen or an alkaline metal, alkaline earth metal or optionally substituted ammonium ion; m, n and p are integers each being equal to the charge of M, N or Me, respectively; s and r are, independently from each other, 0, 1, 2, 3 or 4, with the proviso that (i) r, s and q cannot simultaneously be 0; and (ii) the number of hydrogens in the meaning of M or N may be 0, 1 or 2, as well as pharmaceutical compositions containing these compounds. The compounds and compositions according to the invention can be used for the decorporation of metal ions, mainly radioactive isotopes such as radioactive strontium or cerium being harmful to the living organism. The active agents according to the invention exert their effects either in intravenous or local, transdermal or rectal route of administration.